Date: 04-Sep-2019

UK cost watchdog recommends Novartis' blindness therapy Luxturna

Novartis AG's gene therapy for blindness, Luxturna, is recommended for use on England's public health service, the country's healthcare cost-effectiveness watchdog NICE said on Tuesday. Novartis owns the rights to sell the one-time gene therapy developed by Spark Therapeutics outside the United States. The decision by the National Institute for Health and Care Excellence (NICE) comes as a boost to the Swiss drugmaker, which had come under regulatory scrutiny for data discrepancy issues related to its $2 million gene therapy, Zolgensma.